Apothēka transforms Electronic Medical Records Platforms into secure Blockchain eco-systems. Apothēka systems leverages latest Web 3.0 technology stack (Internet of Things; Artificial Intelligence and Blockchain) to facilitate new advances in patient care, streamlining providers and payers workflow processes while reducing cost. Our technology suite offers distributed blockchain electronic health records, practice management, scheduling, blockchain revenue cycle, smart contracts modules to include a la carte custom agile solutions based on any given client needs. “Elevating Patient Care Experience”

Apothēka transforms Electronic Medical Records Platforms into secure Blockchain eco-systems. Apothēka systems leverages latest Web 3.0 technology stack (Internet of Things; Artificial Intelligence and Blockchain) to facilitate new advances in patient care, streamlining providers and payers workflow processes while reducing cost. Our technology suite offers distributed blockchain electronic health records, practice management, scheduling, blockchain revenue cycle, smart contracts modules to include a la carte custom agile solutions based on any given client needs. “Elevating Patient Care Experience”

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.